Trexquant Investment’s BridgeBio Pharma BBIO Stock Holding History

Trexquant Investment’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-32,930	Closed	-$838K	–	1553
2024 Q3	$838K	Buy	+32,930	New	+$865K	0.01%	1102
2023 Q4	–	Sell	-9,216	Closed	-$243K	–	1428
2023 Q3	$243K	Buy	+9,216	New	+$262K	0.01%	1294
2023 Q1	–	Sell	-143,067	Closed	-$1.09M	–	1440
2022 Q4	$1.09M	Sell	143,067 -11,023	-7%	-$106K	0.03%	615
2022 Q3	$1.53M	Buy	154,090 +91,210	+145%	+$948K	0.05%	410
2022 Q2	$571K	Buy	+62,880	New	+$526K	0.03%	753
2021 Q4	–	Sell	-29,204	Closed	-$1.37M	–	1292
2021 Q3	$1.37M	Buy	29,204 +22,638	+345%	+$1.21M	0.11%	252
2021 Q2	$400K	Buy	6,566 +1,696	+35%	+$96.9K	0.03%	590
2021 Q1	$300K	Buy	+4,870	New	+$319K	0.03%	749
2020 Q4	–	Sell	-12,906	Closed	-$484K	–	1025
2020 Q3	$484K	Sell	12,906 -8,812	-41%	-$277K	0.03%	702
2020 Q2	$708K	Buy	+21,718	New	+$662K	0.05%	533

Other funds holding BBIO

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Trexquant Investment's BBIO Position: Q4 2024 in Review

Trexquant Investment sold out of BridgeBio Pharma (BBIO) in Q4 2024, closing a stake of 32,930 shares — an estimated $838K sold.

Trexquant Investment first reported a position in BBIO in Q2 2020 and held it in 10 quarters. The position peaked at $1.53M in Q3 2022. 263 funds tracked by Wall St. Rank hold BBIO as of Q4 2024.

Trexquant Investment reported no remaining BridgeBio Pharma position as of Q4 2024 after selling out during the quarter.
Trexquant Investment sold 32,930 BridgeBio Pharma shares in Q4 2024, an estimated $838K.
Trexquant Investment first reported a position in BridgeBio Pharma in Q2 2020 and held it in 10 quarters.
Trexquant Investment's BridgeBio Pharma position peaked at $1.53M in Q3 2022.
263 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q4 2024.

Based on Trexquant Investment's 13F filing for Q4 2024, filed 12 Feb 2025.